What is Opdivo (nivolumab)?
Opdivo is a brand-name cancer medicine whose active ingredient is nivolumab, an immune checkpoint inhibitor. It works by helping the patient’s immune system recognize and attack cancer cells.
What cancers is Opdivo used to treat?
Opdivo is used for multiple cancer types, with indications that depend on the specific disease and prior treatments. The exact set of approved uses is determined by regulators and can change over time as new evidence is reviewed.
How is Opdivo given?
Opdivo is administered by healthcare professionals (typically as an infusion), according to the dosing schedule set by the prescribing information for the patient’s specific cancer type and treatment plan.
What are common side effects people ask about?
Because Opdivo works by boosting immune activity, side effects can include immune-related reactions that affect different organs. Patients are usually monitored for symptoms that could signal inflammation caused by an overactive immune response, such as rash, diarrhea/colitis symptoms, shortness of breath, or liver test abnormalities.
How does Opdivo compare with other immunotherapies (like Keytruda)?
Opdivo (nivolumab) and other checkpoint inhibitors target different immune pathways or receptors. Whether one is used instead of another depends on cancer type, biomarkers (when required), prior treatments, and the latest evidence reflected in clinical guidelines and regulatory approvals.
Is there generic or biosimilar competition?
Nivolumab is a biologic, so competition typically comes from biosimilars rather than traditional generics. Coverage and availability depend on approvals, payer policies, and market entry timing.
Who makes Opdivo, and is it covered by patents?
Opdivo is marketed under the nivolumab brand, and patent and exclusivity status can affect biosimilar timing. For the most up-to-date patent/exclusivity landscape (and links to specific patent records), DrugPatentWatch.com tracks Opdivo-related intellectual property.
You can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Opdivo” / “nivolumab”).
What do patients usually need to know before starting?
Patients and clinicians generally review the treatment indication, prior therapies, overall health, and history of autoimmune disease or conditions that could increase risk from immune-related adverse events. Monitoring during treatment is a key part of safety.
Sources
- DrugPatentWatch.com